Name: Induced Pluripotent Stem Cell (iPS Cell) Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3457
Price: 4350 USD
Availability: InStock

Induced Pluripotent Stem Cell Market Size Share and Forecast 2023-2030

Induced Pluripotent Stem Cell (iPS Cell) Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Induced Pluripotent Stem Cell Market is segmented By Type (Human iPSCs, Mouse iPSCs), By Application (Academic Research, Drug Development and Discovery, Toxicity Screening, Regenerative Medicine, Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029.</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The global induced pluripotent stem cell (ips cell) market size was valued US$ XX billion in 2022&nbsp;and is estimated to reach US$ XX billion by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).&nbsp;
</blockquote>

Induced pluripotent stem cells (iPS cell), immature cell generated from an adult (mature) cell and has regained the capacity to differentiate into any cell in the body. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and potentially treat previously incurable diseases.

<h2>Market Dynamics</h2>

The induced pluripotent stem cell (ips cell) market growth is driven by the increasing therapeutic advancements with iPS Cell, growing mergers and acquisitions of organizations to expand their portfolio in iPSCs, Increasing research activities are the major driving factors of the market.

Strong pipeline of iPSC is expected to drive the growth of global induced pluripotent stem cell (ips cell) market during the forecasting period.

The prevalence of chronic diseases worldwide is driving many vendors in the market to develop novel induced pluripotent stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, I Peace Inc. and Avery Therapeutics are collaborating to advance an iPSC-derived cell therapy for heart failure. I Peace is generating the GMP-grade iPSCs, while Avery Therapeutics is using them to manufacture its MyCardia. I Peace can mass production clinical-grade iPSC lines simultaneously in a single room using a miniaturized plate and robotic technology. Its facility is equipped with the fully-closed automated iPSC manufacturing system that meets the safety standards of the U.S. FDA and Japanese PMDA.

Hopstem Biotechnology is one of China&#39;s first iPSC cell therapy companies and a market leader in iPSC-derived clinical-grade cell products. In June 2021, it partnered with Neurophth Biotechnology to co-develop an iPSC-derived cell therapy to treat ocular diseases. Hopstem has a proprietary neural differentiation platform, a patented iPSC reprogramming method, and GMP manufactory and quality systems.

Some major disadvantages of iPSC are likely to hamper the market growth

The primary issue is the use of retroviruses to generate iPSCs as they are associated with cancer, and specifically, retroviruses can insert their DNA anywhere in the genome and subsequently trigger cancer-causing gene expression.

Moreover, in certain non-dividing cell types (such as PBMCs or elderly skin fibroblasts), the reprogramming rate of somatic cells to iPSCs is very low (less than 0.02 %). Thus, there is also a need to assess the quality and variability of the reprogramming process.

PORTER&rsquo;S FIVE FORCES

&nbsp;

<table style="width:100%">
	<tbody>
		<tr>
			<td>
			Competitive

			Rivalry

			(Moderate to High)
			</td>
		</tr>
	</tbody>
</table>

<table style="width:100%">
	<tbody>
		<tr>
			<td>
			Bargaining Power of Suppliers
			</td>
		</tr>
	</tbody>
</table>

<table style="width:100%">
	<tbody>
		<tr>
			<td>
			Bargaining

			Power of

			Buyers
			</td>
		</tr>
	</tbody>
</table>

<table style="width:100%">
	<tbody>
		<tr>
			<td>
			Threat of

			New Entrants
			</td>
		</tr>
	</tbody>
</table>

<table style="width:100%">
	<tbody>
		<tr>
			<td>
			Threat of

			Substitutes
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

<table align="left">
	<tbody>
		<tr>
			<td style="height:516px; width:0px">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
	</tbody>
</table>

Source: DataM Intelligence Analysis (2020)

COVID-19 Impact Analysis

Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization&rsquo;s report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.

According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients and research activities are also holded. Thus, the COVID-19 pandemic has impacted the induced pluripotent stem cell (iPS Cell) market. However, the situation is expected to improve gradually.

<h2>Segment Analysis</h2>

The Human iPSCs segment is expected to hold largest share in this market segment

Animal models don&rsquo;t achieve perfect success results in predicting the pathophysiology of many human diseases because animals differ from humans in physiology, the immune system and individual genetic backgrounds. However, human-induced pluripotent stem cells (iPSCs) are decisive for studying neuronal activity&nbsp;in vitro. Furthermore, human iPSC-derived cells overcome many limitations of other popular models, such as immortalized cell lines and primary mouse neurons, which reproducibility issues can plague and lack biological relevance.

For instance, On October 08, 2020, Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance to Deliver Integrated hiPSC Drug Discovery Solutions

The drug development &amp; discovery segment is expected to hold largest share in this market segment

iPSCs potentially transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery. For instance, BlueRock Therapeutics, a subsidiary of Bayer since August 2019, develops iPSC-derived cell therapies to target Parkinson&rsquo;s disease, heart failure, and ocular diseases.

&nbsp;

<h2>Geographical Analysis</h2>

North America region holds the largest market share of global induced pluripotent stem cell (iPS Cell) market 

North America holds the largest market in the global induced pluripotent stem cell (iPS Cell) market. Currently, the U.S. is the largest target market for pluripotent stem cell (PSC) technology, with more than 2,800 patent families filed. This accounts for more than 50% of the total patent families filed from 2006 to the present and significant market players established in this region. Increasing investments in research &amp; development for product innovations and a positive outlook toward industrial livestock are expected to boost the regional market share. It is widely adopted as a lean meat replacement in North American countries, especially in the U.S. For instance, Semma Therapeutics, which Vertex Pharmaceuticals acquired for $950 million in late 2019, is developing a treatment for Type 1 diabetes. This treatment consists of cells derived from iPSCs that behave like pancreatic cells.

&nbsp;

<h2>Competitive Landscape</h2>

The global induced pluripotent stem cell (ips cell) market is highly competitive with presence of global companies.&nbsp; Some of the key players which are contributing to the growth of the market include Axol Bioscience Ltd, Cynata Therapeutics Limited, Evotec SE, FUJIFILM Cellular Dynamics, Inc, Ncardia, Pluricell Biotech, REPROCELL USA, Inc, Sumitomo Dainippon Pharma Co., Ltd, Takara Bio, Inc, Thermo Fisher Scientific, Inc, Shenzhen Haodi Huatuo Biotechnology Co., Ltd, Wuxi Yingnuui Biomedical Technology, Shanghai Haoran Biotechnology Co., Ltd, ScienCell Research Laboratories, Inc, Beijing Lebo Biotechnology Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Cynata Therapeutics manufacturers iPSC-derived MSCs using its proprietary Cymerus&trade; technology. In partnership with FUJIFILM Corporation, it is clinically testing these cells for the treatment of graft-versus-host disease (GvHD). It is also conducting trials for the treatment of critical limb ischemia (CLI), osteoarthritis (OA), and respiratory failure/distress, including ARDS.

Induced Pluripotent Stem Cell (iPS Cell) Market Key Companies to Watch

FUJIFILM Cellular Dynamics, Inc

Overview: FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human cells used in drug discovery, toxicity testing, stem cell banking, and cell therapy development and founded in 2004 by Dr. James Thomson. The Company partners with innovators worldwide to combine biologically relevant human cells with the newest technologies to drive advancements in medicine and healthier living. Its technology offers the potential to create induced pluripotent stem cells (iPSCs) from anyone, starting with a standard blood draw and followed by the powerful capability to develop into virtually any cell type in the human body.

Product Portfolio: The Company&rsquo;s portfolio comprised of chemical, mechanical, optical, electronic, software and production technologies.

Key Developments: On March 17, 2021, FUJIFILM Cellular Dynamics and Sana Biotechnology Announced License Agreement for the Development of iPSC-Derived Cell Therapies.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the induced pluripotent stem cell (ips cell) market segmentation by type, end-user and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in induced pluripotent stem cell (ips cell) market by analyzing trends and co-development deals.</li>
	<li>Excel data sheet with thousands of data points of induced pluripotent stem cell (ips cell) market - level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global induced pluripotent stem cell (ips cell) market report would provide an access to an approx. 53 market data table, 43 figures and 200 pages.&nbsp; 

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet by Type</li>
		<li>Market Snippet by Application</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Strong pipeline of iPSC</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Some major disadvantages of iPSC</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>PEST Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>&nbsp;Human iPSCs*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Mouse iPSCs</li>
	</ol>
	</li>
	<li>
	<h3>By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment</li>
			<li>Market Attractiveness Index, By Application Segment</li>
		</ol>
		</li>
		<li>&nbsp;Drug Development and Discovery*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Academic Research</li>
		<li>Toxicity Screening</li>
		<li>Regenerative Medicine</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
		<li>Key Companies to Watch</li>
		<li>Company with disruptive technology</li>
		<li>Start Up Companies</li>
	</ol>
	</li>
	<li>
	<h3>Global Induced Pluripotent Stem Cell (iPS Cell) Market- Company Profiles</h3>

	<ol>
		<li>FUJIFILM Cellular Dynamics, Inc*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Axol Bioscience Ltd</li>
		<li>Cynata Therapeutics Limited</li>
		<li>Evotec SE</li>
		<li>Ncardia</li>
		<li>Pluricell Biotech</li>
		<li>REPROCELL USA, Inc</li>
		<li>Sumitomo Dainippon Pharma Co., Ltd</li>
		<li>Takara Bio, Inc</li>
		<li>Thermo Fisher Scientific, Inc</li>
		<li>Shenzhen Haodi Huatuo Biotechnology Co., Ltd</li>
		<li>Wuxi Yingnuui Biomedical Technology</li>
		<li>Shanghai Haoran Biotechnology Co., Ltd</li>
		<li>ScienCell Research Laboratories, Inc</li>
		<li>Beijing Lebo Biotechnology Co., Ltd(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence&nbsp;&nbsp;</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2021,2025 &amp; 2029($ Million)

Table 2 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2021,2025 &amp; 2029($ Million)

Table 3 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Region, 2021,2025 &amp; 2029($ Million)

Table 4 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2021,2025 &amp; 2029($ Million)

Table 5 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2018-2029 ($ Million)

Table 6 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2021,2025 &amp; 2029($ Million)

Table 7 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2018-2029 ($ Million)

Table 8&nbsp;&nbsp;&nbsp;&nbsp; Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Region, 2021,2025 &amp; 2029($ Million)

Table 9 Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Region, 2018-2029 ($ Million)

Table 10&nbsp;&nbsp; North America Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2018-2029 ($ Million)

Table 11&nbsp;&nbsp;&nbsp; North America Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2018-2029 ($ Million)

Table 12&nbsp;&nbsp; North America Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Country, 2018-2029 ($ Million)

Table 13&nbsp;&nbsp; South America Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2018-2029 ($ Million)

Table 14&nbsp;&nbsp; South America Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2018-2029 ($ Million)

Table 15&nbsp;&nbsp; South America Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Country, 2018-2029 ($ Million)

Table 16&nbsp;&nbsp; Europe Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2018-2029 ($ Million)

Table 17&nbsp;&nbsp;&nbsp; Europe Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2018-2029 ($ Million)

Table 18&nbsp;&nbsp; Europe Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Country, 2018-2029 ($ Million)

Table 19&nbsp;&nbsp; Asia-Pacific Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2018-2029 ($ Million)

Table 20&nbsp;&nbsp; Asia-Pacific Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2018-2029 ($ Million)

Table 21&nbsp;&nbsp; Asia-Pacific Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Country, 2018-2029 ($ Million)

Table 22&nbsp;&nbsp; Middle East &amp; Africa Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Type, 2018-2029 ($ Million)

Table 23&nbsp;&nbsp; Middle East &amp; Africa Induced Pluripotent Stem Cell (iPS Cell) Market Value, By Application, 2018-2029 ($ Million)

Table 24&nbsp;&nbsp; FUJIFILM Cellular Dynamics, Inc: Overview

Table 25&nbsp;&nbsp; FUJIFILM Cellular Dynamics, Inc: Product Portfolio

Table 26&nbsp;&nbsp; FUJIFILM Cellular Dynamics, Inc: Key Developments

Table 27&nbsp;&nbsp; Axol Bioscience Ltd: Overview

Table 28&nbsp;&nbsp; Axol Bioscience Ltd: Product Portfolio

Table 29&nbsp;&nbsp; Axol Bioscience Ltd: Key Developments

Table 30&nbsp;&nbsp; Cynata Therapeutics Limited: Overview

Table 31&nbsp;&nbsp; Cynata Therapeutics Limited: Product Portfolio

Table 32&nbsp;&nbsp; Cynata Therapeutics Limited: Key Developments

Table 33&nbsp;&nbsp; Evotec SE: Overview

Table 34&nbsp;&nbsp; Evotec SE: Product Portfolio

Table 35&nbsp;&nbsp; Evotec SE: Key Developments

Table 36&nbsp;&nbsp; Ncardia: Overview

Table 37&nbsp;&nbsp; Ncardia: Product Portfolio

Table 38&nbsp;&nbsp; Ncardia: Key Developments

Table 39&nbsp;&nbsp; Pluricell Biotech: Overview

Table 40&nbsp;&nbsp; Pluricell Biotech: Product Portfolio

Table 41&nbsp;&nbsp; Pluricell Biotech: Key Developments

Table 42&nbsp;&nbsp; REPROCELL USA, Inc: Overview

Table 43&nbsp;&nbsp; REPROCELL USA, Inc: Product Portfolio

Table 44&nbsp;&nbsp; REPROCELL USA, Inc: Key Developments

Table 45&nbsp;&nbsp; Sumitomo Dainippon Pharma Co., Ltd: Overview

Table 46&nbsp;&nbsp; Sumitomo Dainippon Pharma Co., Ltd: Product Portfolio

Table 47&nbsp;&nbsp; Sumitomo Dainippon Pharma Co., Ltd: Key Developments

Table 48&nbsp;&nbsp; Takara Bio, Inc: Overview

Table 49&nbsp;&nbsp; Takara Bio, Inc: Product Portfolio

Table 50&nbsp;&nbsp; Takara Bio, Inc: Key Developments

Table 51&nbsp;&nbsp; Thermo Fisher Scientific, Inc: Overview

Table 52&nbsp;&nbsp; Thermo Fisher Scientific, Inc: Product Portfolio

Table 53&nbsp;&nbsp; Thermo Fisher Scientific, Inc: Key Developments

List of Figures

Figure 1&nbsp;&nbsp;&nbsp; Global Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Type, 2021 &amp; 2029 (%)

Figure 2&nbsp;&nbsp; Global Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Application, 2021 &amp; 2029 (%)

Figure 3&nbsp;&nbsp; Global Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Region, 2021 &amp; 2029 (%)

Figure 4&nbsp;&nbsp; Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 5&nbsp;&nbsp; Global Induced Pluripotent Stem Cell (iPS Cell) Market Y-o-Y Growth, By Type, 2021 &amp; 2029 (%)

Figure 6&nbsp;&nbsp; Human iPSCs: Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 7&nbsp;&nbsp;&nbsp; Mouse iPSCs: Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 8&nbsp;&nbsp; Global Induced Pluripotent Stem Cell (iPS Cell) Market Y-o-Y Growth, By Application, 2021 &amp; 2029 (%)

Figure 9&nbsp;&nbsp; Academic Research: Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 10 Drug Development and Discovery: Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 11&nbsp; Toxicity Screening: Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 12 Regenerative Medicine: Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 13 Others: Global Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 14 Global Induced Pluripotent Stem Cell (iPS Cell) Market Y-o-Y Growth, By Region, 2021 &amp; 2029 (%)

Figure 15 North America Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 16 North America Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Type, 2021 &amp; 2029 (%)

Figure 17&nbsp; North America Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Application, 2021 &amp; 2029 (%)

Figure 18 North America Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 19 South America Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 20 South America Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Type, 2021 &amp; 2029 (%)

Figure 21 South America Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Application, 2021 &amp; 2029 (%)

Figure 22 South America Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 23 Europe Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 24 Europe Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Type, 2021 &amp; 2029 (%)

Figure 25 Europe Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Application, 2021 &amp; 2029 (%)

Figure 26 Europe Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 27 Asia-Pacific Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 28 Asia-Pacific Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Type, 2021 &amp; 2029 (%)

Figure 29 Asia-Pacific Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Application, 2021 &amp; 2029 (%)

Figure 30 Asia-Pacific Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 31 Middle East &amp; Africa Induced Pluripotent Stem Cell (iPS Cell) Market Value, 2018-2029 ($ Million)

Figure 32 Middle East &amp; Africa Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Type, 2021 &amp; 2029 (%)

Figure 33 Middle East &amp; Africa Induced Pluripotent Stem Cell (iPS Cell) Market Share, By Application, 2021 &amp; 2029 (%)

Figure 34 FUJIFILM Cellular Dynamics, Inc: Financials

Figure 35 Axol Bioscience Ltd: Financials

Figure 36 Cynata Therapeutics Limited: Financials

Figure 37 Evotec SE: Financials

Figure 38 Ncardia: Financials

Figure 39 Pluricell Biotech: Financials

Figure 40 REPROCELL USA, Inc: Financials

Figure 41 Sumitomo Dainippon Pharma Co., Ltd: Financials

Figure 42 Takara Bio, Inc: Financials

Figure 43 Thermo Fisher Scientific, Inc: Financials